非小细胞肺癌晚期靶向药物治疗中血清肿瘤标志物预测疗效的临床意义

Clinical Significance of Serum Tumor Markers in Predicting Outcomes of Targeted Therapy in Advanced Non-Small Cell Lung Cancer

目的:探讨晚期非小细胞癌患者靶向治疗前后血清肿瘤标志物预测疗效的临床意义。方法:对抽取的90例晚期非小细胞肺癌患者采用靶向药物治疗,评价治疗前后血清标志物水平的变化及近期疗效。结果:41例部分缓解(PR),31例稳定病变(SD),18例进展(PD),有效率45.56%;PR组、SD组、PD组的CEA、CA125、Cyfra21-1、SCCAg、NSE治疗前后的差值经方差分析,差异有统计学意义(F=36.172,P=0.000),PR组的差值高于其他两组,差异有统计学意义(P<0.05);治疗后较治疗前有效组的CEA、CA125、Cyfra21-1、SCCAg、NSE均显著降低且差异具有统计学意义(P<0.05),治疗后有效组和对照组的各指标差值比较差异具有统计学意义(P<0.05)。结论:血清肿瘤标志物水平能有效的预测靶向治疗药物治疗晚期非小细胞肺癌的疗效,有重要临床参考价值。

Objective：To study the clinical significance of serum tumor markers in predicting outcomes before and after targeted therapy in patients with advanced non-small cell cancer.Methods：Extracted 90 patients with advanced non-small cell lung cancer received targeted drug treatment,and the change of serum marker levels before and after the treatment as well as recent outcomes were evaluated.Results：41 cases with partial response （PR）,31 patients with stable disease （SD）,18 patients with progressive disease （PD）,effective rate was 45.56％; the differences in PR group,SD group,PD group,CEA,CA125,Cyfra21-1,SCCAg and NSE before and after treatment were processed using analysis of variance,and the difference was statistically significant （F=36.172,P=0.000）,the difference in PR group was statistically significantly higher than the other two groups （P＜0.05）; compared with those before the treatment,values of Group CEA,CA125,Cyfra21-1,SCCAg and NSE after the treatment were significantly decreased with statistically significant difference （P＜0.05）; and there were statistically significant difference in all indice between effective group and control group after the treatment （P＜0.05）.Conclusion：Serum tumor marker levels can effectively predict efficacy of targeted drug therapy of advanced non-small cell lung cancer with an important clinical reference value.